1. Vías de señalización
  2. Epigenetics
    JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
    Stem Cell/Wnt
  3. JAK

JAK

Janus kinase

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.

Cat. No. Nombre del producto Efecto Pureza Chemical Structure
  • HY-112391
    SD-1029
    Inhibitor
    SD-1029 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.
    SD-1029
  • HY-171366
    lirucitinib
    Inhibitor 98.72%
    lirucitinib is a JAK inhibitor, and has antiinflammatory activity. lirucitinib inhibits various itch- and inflammation-inducing cytokines that depend on JAK1 enzyme activity, as well as allergy-related cytokines. lirucitinib can be used for the study of pruritic skin diseases
    lirucitinib
  • HY-156273
    HDAC/JAK/BRD4-IN-1
    Inhibitor
    HDAC/JAK/BRD4-IN-1(compound 25ap) is a potent HDAC/JAK/BRD4 triple inhibitor. HDAC/JAK/BRD4-IN-1 inhibit cell growth and induces apoptosis in MDA-MB-231 cells, and shows anticancer activity in vivo.
    HDAC/JAK/BRD4-IN-1
  • HY-100849
    JAK 3i
    Inhibitor 99.81%
    JAK3i is a highly selective JAK3 inhibitor (IC50: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for  autoimmune disease research.
    JAK 3i
  • HY-18316
    RO495
    Inhibitor 98.59%
    RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2 kinase).
    RO495
  • HY-156423
    Tubulin/JAK2-IN-1
    Inhibitor 99.14%
    Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells.
    Tubulin/JAK2-IN-1
  • HY-15315S
    Baricitinib-d5
    Inhibitor 98.98%
    Baricitinib-d5 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
    Baricitinib-d<sub>5</sub>
  • HY-152080
    Blovacitinib
    Inhibitor 99.71%
    Blovacitinib (TUL01101) is a potent, selective and orally active JAK1 inhibitor, with an IC50s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Blovacitinib can be used for the research of rheumatoid arthritis.
    Blovacitinib
  • HY-120692
    Cyclanoline chloride
    Inhibitor
    Cyclanoline chloride is an alkaloid. Cyclanoline chloride can be isolated from Fangji. Cyclanoline (chloride) inhibits the phosphorylation of JAK2 and STAT3, and induces Apoptosis. Cyclanoline chloride suppresses tumor growth in subcutaneous bladder cancer xenograft models of nude mice. Cyclanoline chloride reverses cisplatin resistance in bladder cancer cells and enhances the efficacy of Cisplatin (HY-17394). Cyclanoline chloride can be used for research related to bladder cancer.
    Cyclanoline chloride
  • HY-18300S
    Filgotinib-d4
    Inhibitor 98.0%
    Filgotinib-d4 is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
    Filgotinib-d<sub>4</sub>
  • HY-107594
    Benzene hexabromide
    Inhibitor 98.0%
    Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation.
    Benzene hexabromide
  • HY-13450
    ZM 449829
    Inhibitor 99.73%
    ZM 449829 is a potent, selective and ATP competitive inhibitor of JAK3, with a pIC50 of 6.8. ZM 449829 will be useful pharmacological tools for the investigation of the JAK3.
    ZM 449829
  • HY-148785
    Nimucitinib
    Inhibitor 99.27%
    Nimucitinib is a selective JAK inhibitor with potent tear secretion-promoting activity. Nimucitinib downregulates relevant signal transduction pathways by inhibiting the catalytic activity of JAK family tyrosine kinases. Nimucitinib promotes tear secretion in rabbits and inhibits corneal injury in rats. Nimucitinib can be used in dry eye-related research.
    Nimucitinib
  • HY-16020
    AC-430 hydrobromide
    Inhibitor 99.70%
    AC-430 hydrobromide (example 1) is a potent JAK2 inhibitor. AC-430 hydrobromide can be used for the research of myeloproliferative disorders and cancer.
    AC-430 hydrobromide
  • HY-16379S
    Pacritinib-d4
    Inhibitor 98.42%
    Pacritinib-d8 (SB1518-d8) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).
    Pacritinib-d<sub>4</sub>
  • HY-178500
    WCY-8-67
    Inhibitor
    WCY-8-67 is an orally active and selective USP5 inhibitor, with an IC50 value of 1.33 μM. WCY-8-67 induces apoptosis and suppresses JAK/STAT3 and PI3K/AKT signaling pathways in vitro. WCY-8-67 inhibits proliferation of AE-positive AML cells, induces G1 phase arrest and differentiation of AML cells. WCY-8-67 demonstrates potent anti-leukemic efficacy in mice. WCY-8-67 can be used for the study of acute myeloid leukemia.
    WCY-8-67
  • HY-159536
    Frevecitinib
    Inhibitor 99.42%
    Frevecitinib (KN-002) is a potent pan-JAK inhibitor (i.e. JAK1, JAK2, JAK3, TYK2). Frevecitinib can be used for the study of asthma and other respiratory conditions such as chronic obstructive pulmonary disease (COPD).
    Frevecitinib
  • HY-16997A
    Itacitinib adipate
    Inhibitor 99.18%
    Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.
    Itacitinib adipate
  • HY-161684
    JAK2-IN-10
    Inhibitor
    JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC50 value of ≤10 nM. JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases.
    JAK2-IN-10
  • HY-111471
    JAK-IN-5
    Inhibitor
    JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
    JAK-IN-5
Cat. No. Nombre del producto / Synonyms Species Source
Cat. No. Nombre del producto / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.